Neuroprotection in multiple sclerosis

In chronic inflammatory diseases like multiple sclerosis (MS), neuroprotection refers to strategies aimed at prevention of the irreversible damage of various neuronal and glial cell populations, and promoting regeneration. It is increasingly recognized that MS progression, in addition to demyelination, leads to substantial irreversible damage to, and loss of neurons, resulting in brain atrophy and cumulative disability. One of the most promising neuroprotective strategies involves the use of bone marrow derived stem cells. Both hematopoietic and non-hematopoietic (stromal) cells can, under certain circumstances, differentiate into cells of various neuronal and glial lineages. Neuronal stem cells have also been reported to suppress EAE by exerting direct in situ immunomodulating effects, in addition to their ability to provide a potential source for remyelination and neuroregeneration. Preliminary results from our laboratory indicate that intravenous or intracerebral/intraventricular injection of bone marrow derived stromal cells could differentiate in neuronal/glial cells and suppress the clinical signs of chronic EAE. Both bone marrow and neuronal stem cells may therefore have a therapeutic potential in MS. It seems that future treatment strategies for MS should combine immunomodulation with neuroprotective modalities to achieve maximal clinical benefit.

[1]  E. Brand-Schieber,et al.  Calcium channel blockers ameliorate disease in a mouse model of multiple sclerosis , 2004, Experimental Neurology.

[2]  R. Rudick,et al.  Axonal transection in the lesions of multiple sclerosis. , 1998, The New England journal of medicine.

[3]  K. Rajewsky,et al.  Multiple sclerosis: brain-infiltrating CD8+ T cells persist as clonal expansions in the cerebrospinal fluid and blood. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[4]  H. Lassmann,et al.  The neuroprotective effect of inflammation: implications for the therapy of multiple sclerosis , 2000, Journal of Neuroimmunology.

[5]  D. Compston,et al.  Interferon-beta inhibits mitogen induced astrocyte proliferation in vitro , 1998, Journal of Neuroimmunology.

[6]  Michal Schwartz,et al.  Autoimmunity on alert: naturally occurring regulatory CD4(+)CD25(+) T cells as part of the evolutionary compromise between a 'need' and a 'risk'. , 2002, Trends in immunology.

[7]  Peter K. Stys,et al.  General mechanisms of axonal damage and its prevention , 2005, Journal of the Neurological Sciences.

[8]  R. Hohlfeld,et al.  Secretion of brain-derived neurotrophic factor by glatiramer acetate-reactive T-helper cell lines: Implications for multiple sclerosis therapy , 2005, Journal of the Neurological Sciences.

[9]  J. Benjamins,et al.  Role of calcium in nitric oxide‐induced cytotoxicity: EGTA protects mouse oligodendrocytes , 2001, Journal of neuroscience research.

[10]  W. Brück,et al.  Acute axonal injury in multiple sclerosis. Correlation with demyelination and inflammation. , 2000, Brain : a journal of neurology.

[11]  D. Turnbull,et al.  Mitochondrial dysfunction plays a key role in progressive axonal loss in Multiple Sclerosis. , 2005, Medical hypotheses.

[12]  H. DeLuca,et al.  Vitamin D: its role and uses in immunology 1 , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[13]  P M Matthews,et al.  Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study. , 1998, Brain : a journal of neurology.

[14]  Shrikanth S. Narayanan,et al.  Imaging axonal damage in multiple sclerosis by means of MR spectroscopy , 2000, Neurological Sciences.

[15]  B. Stankoff,et al.  Promoting repair in multiple sclerosis: problems and prospects , 2005, Current opinion in neurology.

[16]  H. Webster,et al.  Growth factors and myelin regeneration in multiple sclerosis , 1997, Multiple sclerosis.

[17]  Angelo L. Vescovi,et al.  Injection of adult neurospheres induces recovery in a chronic model of multiple sclerosis , 2003, Nature.

[18]  Lawrence Steinman,et al.  Multiple sclerosis: a two-stage disease , 2001, Nature Immunology.

[19]  L. Steinman.  Myelin-Specific Cd8 T Cells in the Pathogenesis of Experimental Allergic Encephalitis and Multiple Sclerosis , 2001, The Journal of experimental medicine.

[20]  G. Mancardi,et al.  Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. , 2005, Blood.

[21]  P. Butcher.  Calcium intake and the protein composition of mouse brain: relevance to multiple sclerosis. , 1992, Medical hypotheses.

[22]  E. Hogan,et al.  Increased calpain expression in activated glial and inflammatory cells in experimental allergic encephalomyelitis. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[23]  T. Ben-Hur,et al.  Intraventricular transplantation of neural precursor cell spheres attenuates acute experimental allergic encephalomyelitis , 2003, Molecular and Cellular Neuroscience.

[24]  G. Kreutzberg,et al.  Amyloid precursor protein (APP) expression in multiple sclerosis lesions , 1995, Glia.

[25]  H. Alder,et al.  Oxidative damage to DNA in plaques of MS brains , 1998, Multiple sclerosis.

[26]  B. Trapp,et al.  Axonal and neuronal degeneration in multiple sclerosis: mechanisms and functional consequences , 2001, Current opinion in neurology.

[27]  P. Morris,et al.  In Vitro and In Vivo Effects of Genistein on Murine Alveolar Macrophage TNFα Production , 1999, Inflammation.

[28]  D. Prockop.  Marrow Stromal Cells as Stem Cells for Nonhematopoietic Tissues , 1997, Science.

[29]  Nikos Evangelou,et al.  Quantitative pathological evidence for axonal loss in normal appearing white matter in multiple sclerosis , 2000, Annals of neurology.

[30]  T. Owens.  The enigma of multiple sclerosis: inflammation and neurodegeneration cause heterogeneous dysfunction and damage. , 2003, Current opinion in neurology.

[31]  S. Waxman.  Sodium channels as molecular targets in multiple sclerosis. , 2002, Journal of rehabilitation research and development.

[32]  T. Ben-Hur,et al.  Transplanted multipotential neural precursor cells migrate into the inflamed white matter in response to experimental autoimmune encephalomyelitis , 2003, Glia.

[33]  A J Thompson,et al.  Metabolite changes in normal-appearing gray and white matter are linked with disability in early primary progressive multiple sclerosis. , 2005, Archives of neurology.

[34]  B D Trapp,et al.  Axonal pathology in multiple sclerosis: relationship to neurologic disability. , 1999, Current opinion in neurology.

[35]  T. Dawson,et al.  Free Radicals as Mediators of Neuronal Injury , 1998, Cellular and Molecular Neurobiology.

[36]  Ioannis Milonas,et al.  Axonal damage in multiple sclerosis: a complex issue in a complex disease , 2004, Clinical Neurology and Neurosurgery.

[37]  J. Ludovic Croxford,et al.  Therapeutic Potential of Cannabinoids in CNS Disease , 2003, CNS drugs.

[38]  S. Elkabes,et al.  Plasma membrane calcium ATPase deficiency causes neuronal pathology in the spinal cord: a potential mechanism for neurodegeneration in multiple sclerosis and spinal cord injury , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[39]  S. Doré,et al.  Prostaglandins of J Series Control Heme Oxygenase Expression , 2003, Annals of the New York Academy of Sciences.

[40]  H. Lassmann,et al.  CNTF is a major protective factor in demyelinating CNS disease: A neurotrophic cytokine as modulator in neuroinflammation , 2002, Nature Medicine.

[41]  G. Krissansen,et al.  Simultaneous neuroprotection and blockade of inflammation reverses autoimmune encephalomyelitis. , 2004, Brain : a journal of neurology.

[42]  A. Lo,et al.  Phenytoin protects spinal cord axons and preserves axonal conduction and neurological function in a model of neuroinflammation in vivo. , 2003, Journal of neurophysiology.

[43]  D. Arnold,et al.  Interferon beta promotes nerve growth factor secretion early in the course of multiple sclerosis. , 2005, Archives of neurology.

[44]  R. Tuma,et al.  Win 55212-2, a cannabinoid receptor agonist, attenuates leukocyte/endothelial interactions in an experimental autoimmune encephalomyelitis model , 2004, Multiple sclerosis.

[45]  S. Skaper,et al.  Excitatory amino acid induced oligodendrocyte cell death in vitro: receptor‐dependent and ‐independent mechanisms , 2004, Journal of neurochemistry.

[46]  H. Cross,et al.  Vitamin D and calcium deficits predispose for multiple chronic diseases , 2005, European journal of clinical investigation.

[47]  D. Pitt,et al.  Glutamate excitotoxicity in a model of multiple sclerosis , 2000, Nature Medicine.

[48]  W. Brück,et al.  Tumour necrosis factor alpha mRNA expression in early multiple sclerosis lesions: Correlation with demyelinating activity and oligodendrocyte pathology , 2000, Glia.

[49]  D. Bonnet.  Biology of human bone marrow stem cells , 2003, Clinical and Experimental Medicine.

[50]  S. Lee,et al.  Neuroprotective effect of green tea extract in experimental ischemia-reperfusion brain injury , 2000, Brain Research Bulletin.

[51]  N. Bhat,et al.  TNFα potentiates IFNγ‐induced cell death in oligodendrocyte progenitors , 1998 .

[52]  M. Sela,et al.  Glatiramer acetate-specific T cells in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factor in situ , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[53]  E. Melamed,et al.  Riluzole suppresses experimental autoimmune encephalomyelitis: implications for the treatment of multiple sclerosis , 2003, Brain Research.

[54]  P. Villoslada,et al.  Role of nerve growth factor and other trophic factors in brain inflammation. , 2004, Progress in brain research.

[55]  Guillermo Izquierdo,et al.  Magnetic resonance spectroscopy of normal appearing white matter in early relapsing-remitting multiple sclerosis: correlations between disability and spectroscopy , 2004, BMC neurology.

[56]  M. Chopp,et al.  Human bone marrow stromal cell treatment improves neurological functional recovery in EAE mice , 2005, Experimental Neurology.

[57]  V. Gallai†,et al.  Excitatory amino acids and multiple sclerosis: evidence from cerebrospinal fluid. , 2003, Archives of neurology.

[58]  P. Ye,et al.  Insulin-Like Growth Factor I Protects Oligodendrocytes from Tumor Necrosis Factor-α-Induced Injury. , 1999, Endocrinology.

[59]  H. Okano,et al.  Caspase-mediated oligodendrocyte cell death in the pathogenesis of autoimmune demyelination , 2003, Neuroscience Research.

[60]  M. Ameloot,et al.  Immune-mediated oligodendrocyte injury in multiple sclerosis: molecular mechanisms and therapeutic interventions. , 2002, Critical reviews in immunology.

[61]  J. Kordower,et al.  Inhibitors of Cyclooxygenase-2, but Not Cyclooxygenase-1 Provide Structural and Functional Protection against Quinolinic Acid-Induced Neurodegeneration , 2003, Journal of Pharmacology and Experimental Therapeutics.

[62]  Kenneth J. Smith,et al.  Inflammation and primary demyelination induced by the intraspinal injection of lipopolysaccharide , 2005, Brain : a journal of neurology.

[63]  M. Salinas,et al.  Caspase inhibitors protect against neuronal apoptosis induced by cerebrospinal fluid from multiple sclerosis patients , 2003, Journal of Neuroimmunology.

[64]  B. Trembly.  Clinical Potential for the Use of Neuroprotective Agents. A Brief Overview , 1995, Annals of the New York Academy of Sciences.

[65]  M. Palkovits,et al.  Axonal changes in chronic demyelinated cervical spinal cord plaques. , 2000, Brain : a journal of neurology.

[66]  S. Sakoda,et al.  Nitric oxide via an inducible isoform of nitric oxide synthase is a possible factor to eliminate inflammatory cells from the central nervous system of mice with experimental allergic encephalomyelitis , 1997, Journal of Neuroimmunology.

[67]  Michal Schwartz,et al.  Neuroprotective autoimmunity: Naturally occurring CD4+CD25+ regulatory T cells suppress the ability to withstand injury to the central nervous system , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[68]  V. Yong,et al.  Interferon‐β Is a Potent Promoter of Nerve Growth Factor Production by Astrocytes , 1997, Journal of neurochemistry.

[69]  L. Turski,et al.  Autoimmune encephalomyelitis ameliorated by AMPA antagonists , 2000, Nature Medicine.

[70]  Daniel Offen,et al.  The role of oxidative stress in the pathogenesis of multiple sclerosis: The need for effective antioxidant therapy , 2004, Journal of Neurology.